NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) --   Rubenstein Public Relations (RPR), a leading full-serv

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader i

Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS

OS Therapies Inc. (NYSE:OSTX) announced a statistically significant three-year overall survival bene

OS Therapies reports a 72.7% three-year survival rate in its Phase 2b osteosarcoma trial, preparing

Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients

Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader i

Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch

New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, In

Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirm

Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirm

The Company aligned with the FDA on the use of the proposed adaptive design agreed upon with the U.K

FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial After successful Scientific Advice

MHRA agreed that the use of comparable historical control data – derived from a systematic evaluatio

Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submission

OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for

Overall survival data when compared with a combined published historical control arm being used for

71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical

Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Invest

Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax c

Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September,

Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September

Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i

CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i

Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA

Company secures $10 million line of credit supported by OS Therapies UK tax credits New York, New Yo

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i

Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on stati

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs p

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995) Over 15,000 dogs

Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the

Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the

OS Therapies Incorporated (NYSE:OSTX) shares are up during Tuesday's premarket session as the compan

OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no ne

Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the pric

OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst con

Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune

New patent application covers treatment-emergent immune signature related to 'turning cold tumor

OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst con

OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i

Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with ex

FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated

OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK,